University of California, Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

University of California, Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile

University of California, Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
University of California, Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
36 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

University of California, Los Angeles (UCLA) a subsidiary of University of California is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The universitys services include support services, campus services, graduate degree and undergraduate degree program and also provides research services in libraries, museums, film, music archives, art galleries, horizon-broadening, humanity-serving of California. UCLA operates through its departments including anthropology, archaeology, applied linguistics, architecture and urban design, bio-engineering, bio-medical research, dentistry and digital humanities.

University of California, Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have

  
Source:
Document ID
GDPH73202D
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
University of California, Los Angeles, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
University of California, Los Angeles, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
University of California, Los Angeles, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
University of California, Los Angeles, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
University of California, Los Angeles, Medical Devices Deals, 2010 to YTD 201691
University of California, Los Angeles, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016102
University of California, Los Angeles, Pharmaceuticals &Healthcare, Deal Details1219
  Partnerships121
    InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles121
    Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies132
    Trethera Enters into Research Agreement with University of California, Los Angeles151
    Bristol-Myers Squibb Enters into Research Agreement with UCLA161
    BioNano Genomics Enters into Research Agreement with University of California, Los Angeles171
    Zymeworks Enters into Research Agreement with University of California, Los Angeles181
    NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development191
    UCLA Medical Center Forms Joint Venture With First Affiliated Hospital Of Medical School201
    Prometheus Labs Enters Into Research Agreement With University Of California211
  Licensing Agreements221
    Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles221
    Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies231
    Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology241
    Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles251
    BioTime Enters Into Licensing Agreement With University of California, Los Angeles261
    Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment271
    Fibrocell Science Enters Into Licensing Agreement With University of California281
  Asset Transactions291
    Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion292
University of California, Los Angeles - Key Competitors311
Key Employees321
Locations And Subsidiaries333
  Head Office331
  Other Locations &Subsidiaries333
Appendix361
  Methodology361
  About GlobalData361
  Contact Us361
  Disclaimer361

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "University of California, Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/University-of-California-Los-Angeles-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-17182>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). University of California, Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/University-of-California-Los-Angeles-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-17182>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research